Favorable Effects of Tacrolimus Monotherapy on Myasthenia Gravis Patients

Background and Purpose: Tacrolimus (TAC) has been proven to be a rapid-acting, steroid-sparing agent for myasthenia gravis (MG) therapy. However, evidence related to the effectiveness of TAC alone is rare. Therefore, this study was performed to investigate the effect of TAC monotherapy in MG patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Zhirong, Li, Zunbo, Shen, Faxiu, Zhang, Xueping, Lei, Lin, Su, Shengyao, Lu, Yan, Di, Li, Wang, Min, Xu, Min, Da, Yuwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7652845/
https://www.ncbi.nlm.nih.gov/pubmed/33193063
http://dx.doi.org/10.3389/fneur.2020.594152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7652845/
https://www.ncbi.nlm.nih.gov/pubmed/33193063
http://dx.doi.org/10.3389/fneur.2020.594152

Ejemplares similares